Skip to main content
Clinical Trials/NCT03347877
NCT03347877
Enrolling By Invitation
Not Applicable

Clinical Study of Autologous Osteo-periosteal Cylinder Graft Transplantation for Hepple V Osteochondral Lesions of the Talus

Peking University Third Hospital1 site in 1 country70 target enrollmentJanuary 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteochondral; Defect
Sponsor
Peking University Third Hospital
Enrollment
70
Locations
1
Primary Endpoint
American Orthopaedic Foot & Ankle Society(AOFAS) ankle-hindfoot score
Status
Enrolling By Invitation
Last Updated
8 months ago

Overview

Brief Summary

The trial evaluates the clinical efficacy and safety of autologous osteo-periosteal cylinder graft transplantation for Hepple V osteochondral lesions of the talus. Half of participants will receive autologous osteo-periosteal cylinder graft transplantation, while the other will receive osteochondral graft transplantation as a control group.

Detailed Description

Autologous osteo-periosteal cylinder graft surface is a periosteal structure, with the ability of repairment to cartilage, periosteum is closely connected to the cortical bone, then the deep loose cancellous bone.The objective of the study is to evaluate the clinical efficacy of autologous osteo-periosteal cylinder graft transplantation for Hepple V osteochondral lesions of the talus by randomized controlled trial. 70 patients with clinically diagnosed Hepple V talus osteochondral lesions according to 1: 1 were divided into experimental group and control group. The experimental group will be treated with autologous osteo-periosteal cylinder graft transplantation under arthroscopy. The control group will be treated with autologous osteochondral graft under arthroscopy. The patients will be treated by the same surgeon in this study group. Postoperative MRI MOCART evaluation, clinical AOFAS score, VAS score, Tegner score, and the secondary arthroscopy ICRS score will be selected as the measures of outcome. The incidence of adverse events will be recorded.

Registry
clinicaltrials.gov
Start Date
January 1, 2018
End Date
December 31, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Guo Qinwei

Principal Investigator, Clinical Associate Professor and Chief Orthopedist of Orthopedic Sports Medicine

Peking University Third Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-50 years old, male or female
  • Chronic pain in the ankle, confirmed by ankle joint MRI as Hepple V osteo-chondral lesions of the talus
  • Using rest/external use/oral non-steroidal anti-inflammatory drugs and other conservative treatment for more than 3 months ineffective
  • Patients voluntarily participated in clinical trials, signed informed consent, with clinical follow-up

Exclusion Criteria

  • In the last 6 months patients participated in other drug or medical device clinical trials
  • Line of force in ankle is not correct (varus or valgus\> 5 degrees)
  • Grade III ankle collateral ligament injury
  • Chronic specific synovitis (rheumatoid, pigmented villonodular synovitis, etc.)
  • Joint fibrosis, ankylosis, activity was significantly limited
  • Moderate and severe osteoarthritis
  • There are MRI contraindications
  • Hemophilia patients
  • The general condition of patients can not tolerate surgery
  • Pregnant or planned pregnant women and lactating women

Outcomes

Primary Outcomes

American Orthopaedic Foot & Ankle Society(AOFAS) ankle-hindfoot score

Time Frame: 4 years

American Orthopaedic Foot \& Ankle Society(AOFAS) ankle-hindfoot score. The higher score represent the better outcome.

Secondary Outcomes

  • Tegner activity level score(4 years)
  • International Cartilage Repair Society(ICRS) score(4 years)
  • Magnetic Resonance Observation of cartilage repair tissue(MOCART) score(4 years)
  • Visual analogue scale(4 years)

Study Sites (1)

Loading locations...

Similar Trials